Cyplasin Biomedical Ltd Announces Japanese Patent for its Antitumor Protein

27-May-2008

Cyplasin Biomedical Ltd announced that its Japanese Patent application Nr Hei 9-516992 has been granted. The claims cover the characterization of a cytotoxic protein from the mucus of the sea hare Aplysia punctata and its use to treat cancer.

"It is gratifying to receive the approval of our patent application since it was obtained after many years of careful in-depth-analysis by the Japanese Patent Office. It describes our intellectual property for the cytotoxic Cyplasin to be used as an anticancer substance, especially valuable in one of the most important economies worldwide. Together with corresponding US and European patents Cyplasin Biomedical Ltd relies now on a solid intellectual property portfolio allowing it to proceed successfully in the rapid development of Cyplasin," said Professor Christian Petzelt, Chief Scientific Officer of Cyplasin Biomedical Ltd.

Cyplasin-SC TM has demonstrated a selective ability to rapidly kill certain types of cancer cells while leaving normal non-cancerous cells untouched. Cyplasin-SC TM is a protein originally discovered and isolated by Professor Petzelt from a marine organism, the sea hare (Aplysia punctata). The protein can now be manufactured as a recombinant protein which allows the company to develop the protein as an anti-cancer therapeutic product. United States and European Patents have been issued to the Company covering the Cyplasin-SC TM protein.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance